CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$2.75
0.00 (0.00%)
▲
5d:
+0.0%
30d:
+0.0%
90d:
+7.0%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Smart Money Accumulation
None View Scanner →
Strength: 4.6/10
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CRON this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 4.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CRON shows positive signals but monitor for confirmation. Market pricing in 4.4% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $2.75, which is considered fair relative to its 30-day fair value range of $2.68 to $2.81. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.6) compared to its historical average (21.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $2.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $2.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.68 -
$2.81
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($2.51)
Trading Range Analysis
30-Day Trading Range
$2.68 -
$2.81
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.72
Resistance Level
$2.94
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.62
Wall Street Target
$2.51
(-8.6%)
Revenue Growth (YoY)
40.1%
Earnings Growth (YoY)
126.8%
Profit Margin
-1.1%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
18.6 vs 21.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$2.63
(-4%)
2-Year Target
$2.51
(-9%)
3-Year Target
$2.40
(-13%)
3-Yr Target (if PE normalizes)
(PE: 19→21)
$2.75
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 12.5%)
$4.58
(+67%)
Base:
(SPY PE: 18.6, Growth: 12.5%)
$3.91
(+42%)
Bear:
(PE: 15.8, Growth: 12.5%)
$3.33
(+21%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.6 to 21.3
Stabilization Target:
$3.15
(+14.4%)
PE Expansion Potential:
+14.4%
Share & Embed Analysis
Last updated: July 14, 2026 5:55 PM ET
Data refreshes hourly during market hours. Next update: 6:55 PM
Data refreshes hourly during market hours. Next update: 6:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
